Friday 6 November 2026
Export PHG’s income statement to Excel — free account
Koninklijke Philips N.V.
PHG Healthcare Medical Devices
Koninklijke Philips N.V.’s revenue for fiscal 2025 (year ended December 2025) was $20.2 billion, up 3.47% from fiscal 2024.
- Revenue
- +0.55%
- EPS
- −85.0%
- Free cash flow
- +154.2%
- Total debt
- −4.96%
Quarter to September 2026, against a year earlier
30.29
0.22
−0.72%
Follow PHG
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
20.67 | 19.86 | 22.85 | 24.87 |
+8 more quarters Free account |
P/S ratio |
1.16 | 1.26 | 1.28 | 1.27 | |
P/FCF ratio |
11.28 | 14.05 | 14.78 | 44.24 | |
P/Operating CF |
38.55 | 59.63 | 118.50 | 16.23 | |
P/B ratio |
1.79 | 1.95 | 1.95 | 2.07 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.39 | 1.51 | 1.52 | 1.50 | |
EV/EBITDA |
9.23 | 9.19 | 10.26 | 10.50 | |
EV/Operating CF |
10.04 | 11.98 | 12.26 | 22.83 | |
EV/FCF |
13.56 | 16.85 | 17.59 | 52.15 | |
Quick Ratio |
0.81 | 0.73 | 0.80 | 0.86 | |
Current Ratio |
1.33 | 1.26 | 1.32 | 1.32 | |
Net Debt/EBITDA |
10.12 | 4.51 | 8.34 | 5.15 | |
Debt/Assets |
24.92% | 23.65% | 25.27% | 25.73% | |
Debt/Equity |
0.60 | 0.55 | 0.60 | 0.63 | |
Asset Turnover |
0.65 | 0.67 | 0.68 | 0.65 | |
Operating CF/Net income |
19.94 | 0.98 | 1.25 | 3.55 | |
Capex/Depreciation |
(0.63) | (0.40) | (0.60) | (0.70) | |
Interest Coverage |
1.96 | 6.42 | 2.90 | 4.94 | |
Research and Development Expense of Revenue |
9.33% | 11.10% | 10.09% | 8.49% | |
Selling, General and Administrative Expense of Revenue |
26.72% | 27.68% | 30.32% | 25.81% | |
Intangible Assets out of Total Assets |
0.44 | 0.46 | 0.45 | 0.44 | |
Share Based Compensation of Revenue |
0.96% | 1.17% | 0.77% | 0.50% | |
Graham Net Nets |
(0.28) | (0.26) | (0.27) | (0.27) | |
Graham Number |
19.07 | 20.74 | 19.46 | 17.92 | |
Earnings Yield |
4.84% | 5.03% | 4.38% | 4.02% | |
Free Cash Flow Yield |
8.86% | 7.12% | 6.76% | 2.26% | |
Revenue per Share |
5.17 | 5.31 | 4.80 | 6.23 | |
Operating CF per Share |
0.63 | 0.46 | 0.23 | 1.67 | |
Capex per Share |
(0.18) | (0.18) | (0.20) | (0.21) | |
Free Cash Flow per Share |
0.45 | 0.27 | 0.03 | 1.46 | |
Cash per Share |
3.30 | 2.25 | 3.28 | 3.43 | |
Shareholders Equity per Share |
13.67 | 13.96 | 14.04 | 13.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.67 | 13.96 | 14.04 | 13.11 | |
Free Cash Flow |
440.20 | 259.07 | 32.77 | 1,384.61 | |
Working Capital |
2,990.30 | 2,218.43 | 2,753.95 | 2,741.38 | |
Capital Expenditures |
(179.35) | (176.66) | (187.26) | (197.38) | |
Net Current Asset Value |
(6,803.56) | (6,854.12) | (7,097.31) | (6,813.30) | |
EV/EBIT |
16.04 | 15.71 | 17.93 | 18.79 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.03 | |
Price to Operating Income |
13.35 | 13.10 | 15.07 | 15.94 | |
| Other line items | |||||
Average Receivables |
4,021.97 | 3,979.52 | 3,766.77 | 4,150.20 | |
Average Payables |
2,230.43 | 3,010.77 | 2,128.50 | 2,086.24 | |
Average Inventory |
3,864.31 | 3,704.10 | 3,574.58 | 3,568.44 | |
Average Assets |
31,523.37 | 30,495.35 | 30,266.28 | 31,112.50 | |
Average Common Equity |
12,866.80 | 12,580.31 | 12,858.43 | 12,633.70 |
Columns are period end dates · fundamentals updated 5 Nov 2026